Shares of Cardio Diagnostics Holdings Inc (NASDAQ:CDIO) climbed about 9.3% in premarket trading on Wednesday after the company unveiled plans to expand into India, marking its first move beyond the U.S. market.
The AI-enabled cardiovascular diagnostics specialist said it has entered into a strategic partnership to introduce its PrecisionCHD blood test in India. The collaboration brings together Aimil Ltd., a long-established Indian instrumentation company founded in 1932, and Dr. Lal PathLabs, one of the country’s largest diagnostic networks with more than 290 clinical laboratories. The initiative aims to make Cardio Diagnostics’ coronary heart disease (CHD) detection test available in a market where cardiovascular disease remains a major public health challenge.
PrecisionCHD integrates epigenetics, genetics and artificial intelligence to identify coronary heart disease at the molecular level. Unlike conventional angiograms, the test is designed to detect both obstructive and non-obstructive forms of CHD, including conditions such as Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA).
According to the company, the initial phase of the partnership is already underway and is focused on integrating PrecisionCHD into Dr. Lal PathLabs’ laboratory network, while ensuring compliance with local clinical practices and regulatory requirements. A broader commercial launch of the test is targeted for 2026.
Cardio Diagnostics highlighted the scale of the opportunity in India, noting that the prevalence of coronary heart disease is estimated at up to 7.4% in rural populations and as high as 13% in urban areas, underscoring the potential demand for advanced diagnostic solutions.